Naunyn-Schmiedeberg's archives of pharmacology最新文献

筛选
英文 中文
Untargeted metabolomics revealed that quercetin improves rat renal metabolic disorders induced by chronic unpredictable mild stress. 非靶向代谢组学显示,槲皮素可改善慢性不可预测的轻度应激引起的大鼠肾脏代谢紊乱。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-25 DOI: 10.1007/s00210-025-04186-9
Yali Hou, Yaru Li, Jian Li, Xiujuan Zhao
{"title":"Untargeted metabolomics revealed that quercetin improves rat renal metabolic disorders induced by chronic unpredictable mild stress.","authors":"Yali Hou, Yaru Li, Jian Li, Xiujuan Zhao","doi":"10.1007/s00210-025-04186-9","DOIUrl":"10.1007/s00210-025-04186-9","url":null,"abstract":"<p><p>Depression is a serious mental disease, and its accompanying abnormal changes in peripheral organs, including the kidney, are easy to be ignored. The metabolic abnormalities of the kidney and other organs will inevitably affect the progress of depression through the circulatory system. Quercetin has attracted much attention as a flavonoid with anti-inflammatory, antioxidant, neuroprotective, and antidepressant potential. Chronic unpredictable mild stress (CUMS) model is a reliable and effective animal model of depression. We hypothesize that quercetin has the potential to alleviate the abnormalities in renal metabolic profile induced by CUMS. An ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) platform was used to analyze renal metabolites, and the obtained data were analyzed using the Progenesis QI software for peak alignment, peak picking, and data normalization. Based on the data processing method with fold change > 2 or < 0.5, the false discovery rate corrected was p < 0.05, and a variable importance in projection score was > 1; a total of 16 differential metabolites were identified, including L-histidine, D-glucose 1-phosphate, cytidine, D-Ribulose 5-phosphate, D-xylulose 5-phosphate, uridine monophosphate (UMP), uracil, glucuronide, prostaglandin-F2α (PGF2ɑ), arachidonic acid, 14,15-dihydroxyeicosatrienoic acid (14,15-DHET), 14,15-epoxyeicosatrienoic acid (14,15-EET), deoxycytidine, anserine, carnosine, and PC (14:0). Among them, the intensities of anserine, carnosine, L-histidine, and 14,15-EET were significantly reduced (p < 0.01), while the intensities of other metabolites were significantly increased in the CUMS group compared with the control group (p < 0.01). When CUMS model rats received high-dose quercetin treatment, the intensities of above differential metabolites were significantly restored (p < 0.05 or p < 0.01). Further, pathway enrichment analysis revealed abnormalities in arachidonic acid (AA) metabolism, pyrimidine metabolism, amino acid metabolism, and pentose and glucuronide acid interconversion in the kidney. The renal histopathological examination revealed CUMS induced renal tubular epithelial cell shedding and glomerular atrophy. High-dose quercetin can improve renal metabolic disorders and renal pathological changes caused by CUMS. Mechanistically, quercetin improves renal metabolic disorders by enhancing the antioxidant capacity and inhibiting the secretion of inflammatory factors. Moreover, quercetin can regulate renal AA metabolism disorder by inhibiting soluble epoxide hydrolase activity. High-dose quercetin (50 mg/kg bw) has a certain protective effect on kidney damage induced by CUMS, providing new strategies for quercetin to prevent depression.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"14257-14271"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement. 超越肥胖:瘦代谢功能障碍相关的脂肪性肝炎从揭示分子发病机制到治疗进展。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-05-14 DOI: 10.1007/s00210-025-04257-x
Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam
{"title":"Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement.","authors":"Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam","doi":"10.1007/s00210-025-04257-x","DOIUrl":"10.1007/s00210-025-04257-x","url":null,"abstract":"<p><p>Nonalcoholic fatty liver disease (NAFLD), now known by the name of metabolic dysfunction-associated fatty liver disease (MAFLD), with increased global incidence, has been recognized as a significant metabolic disorder. NAFLD includes a spectrum liver disease from hepatocellular fat accumulation (isolated steatosis) to an advanced form of liver injury known as nonalcoholic steatohepatitis (NASH), which refers to distinct histologic features, including hepatocellular steatosis and injury, necroinflammation, and eventually fibrosis. Nonobese or lean individuals associated with metabolic dysregulation usually demonstrated diverse risk factors compared to obese MAFLD. The presence of normal range body mass index (BMI) and excess visceral adiposity with increased cardiometabolic and renal comorbidities, along with sarcopenia, has been evidenced to be associated with lean MASH. Genetic predispositions accompanying lifestyle and environmental factors contribute to disease initiation and progression. The genetic influence in pathophysiology indicated the significant contributions of the following genes: PNPLA3, TM6SF2, APOB, LIPA, MBOAT7, and HSD17B13, and the impact of their disease-specific variants in the development of obesity-independent MASH. The epigenetic modifications exhibited differential DNA methylation patterns in the genes involved in lipid metabolism, particularly hypomethylation of PEMT. Diet-induced and genetic animal models of lean MASH, including Slc: Wistar/ST rats, PPAR-α, PTEN, and MAT1A knockout mice models, are indicated to be pivotal in the exploration of disease progression and observing the effect of therapeutic interventions. This comprehensive review comprises the molecular and genetic pathophysiology, molecular diagnostics, and therapeutic aspects of lean MASH to enunciate a diagnostic approach that combines detailed clinical phenotyping regarding genomic analysis.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13647-13665"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Antibiofilm activity of exopolysaccharide-mediated ZnO nanoparticle against Pseudomonas aeruginosa biofilm. 外多糖介导的氧化锌纳米颗粒对铜绿假单胞菌生物膜的抗菌活性。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 DOI: 10.1007/s00210-025-04569-y
Rosalin Nath, Dibyajit Lahiri, Moupriya Nag, Debanjana Mahapatra, Manoswinee Bhattacharya, Kakoli Dutta, Debasmita Bhattacharya
{"title":"Retraction Note: Antibiofilm activity of exopolysaccharide-mediated ZnO nanoparticle against Pseudomonas aeruginosa biofilm.","authors":"Rosalin Nath, Dibyajit Lahiri, Moupriya Nag, Debanjana Mahapatra, Manoswinee Bhattacharya, Kakoli Dutta, Debasmita Bhattacharya","doi":"10.1007/s00210-025-04569-y","DOIUrl":"10.1007/s00210-025-04569-y","url":null,"abstract":"","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"14551"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammasomes and autophagy in cancer: unlocking targeted therapies. 癌症中的炎性小体和自噬:解锁靶向治疗。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-05-01 DOI: 10.1007/s00210-025-04184-x
Jitendra Gupta, Mohammed Hashim Mohammed, Tawfeeq Alghazali, Subasini Uthirapathy, Roopashree R, Vishal Thakur, Manpreet Kaur, K Satyam Naidu, Aziz Kubaev, Mahmoud Mussleh Al-Mukhtar
{"title":"Inflammasomes and autophagy in cancer: unlocking targeted therapies.","authors":"Jitendra Gupta, Mohammed Hashim Mohammed, Tawfeeq Alghazali, Subasini Uthirapathy, Roopashree R, Vishal Thakur, Manpreet Kaur, K Satyam Naidu, Aziz Kubaev, Mahmoud Mussleh Al-Mukhtar","doi":"10.1007/s00210-025-04184-x","DOIUrl":"10.1007/s00210-025-04184-x","url":null,"abstract":"<p><p>This study clarifies the interaction between autophagy and inflammasome within the cancer framework. The inflammasome generates pro-inflammatory cytokines to direct the immune response to pathogens and cellular stressors. Autophagy maintains cellular homeostasis and can either promote or inhibit cancer. These pathways interact to affect tumorigenesis, immune responses, and therapy. Autophagy controls inflammasome activity by affecting cancer pathogenesis and tumor microenvironment inflammation, highlighting novel cancer therapeutic approaches. Recent studies indicate that modulating autophagy and inflammasome pathways can boost anti-cancer immunity, reduce drug-resistance, and improve therapeutic efficacy. Recent studies indicate modulating inflammasome and autophagy pathways can augment anti-cancer immunity, mitigate therapy resistance, and improve treatment efficacy. Cancer research relies on understanding the inflammasome-autophagy relationship to develop targeted therapies that enhance anti-tumor efficacy and reduce inflammatory symptoms. Customized therapies may improve outcomes based on autophagy gene variations and inflammasome polymorphisms. This study investigates autophagy pathways and the inflammasome in tumor immunopathogenesis, cytokine function, and cancer therapeutic strategies, highlighting their significance in cancer biology and treatment.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13295-13320"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geniposide protects against cerebral ischemic injury by targeting SOX2/RIPK1 axis. 京尼平苷通过靶向SOX2/RIPK1轴保护脑缺血损伤。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-21 DOI: 10.1007/s00210-025-04079-x
Xiaogang He, Yi Zhang, Chunyang Xu, Rong Zhang, Ya Li
{"title":"Geniposide protects against cerebral ischemic injury by targeting SOX2/RIPK1 axis.","authors":"Xiaogang He, Yi Zhang, Chunyang Xu, Rong Zhang, Ya Li","doi":"10.1007/s00210-025-04079-x","DOIUrl":"10.1007/s00210-025-04079-x","url":null,"abstract":"<p><p>Convincing evidence has indicated that geniposide possesses neuroprotective effects in ischemic stroke. This study is designed to explore the potential molecular mechanism of geniposide in oxygen-glucose deprivation/reoxygenation (OGD/R)-treated BV-2 microglial cells and middle cerebral artery occlusion (MCAO) mice. OGD/R model in BV2 microglial cells was established in this research. Cell viability and apoptosis were determined using Cell Counting Kit-8 (CCK-8) and flow cytometry assays. Protein levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), microtubule-associated protein light chain 3 (LC3)-II/LC3-I, Beclin-1, inducible nitric oxide synthase (iNOS), CD86, sex determining region Y-box 2 (SOX2), receptor-interacting serine/threonine-protein kinase 1 (RIPK1), TNF-α, IL-1β, ARG1, and CD163 were detected by western blot assay. RIPK1 mRNA level was determined using real-time quantitative polymerase chain reaction (RT-qPCR). TNF-α and IL-1β levels were analyzed using ELISA kits. After JASPAR analysis, binding between SOX2 and RIPK1 promoter was predicted and verified using chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. The effects of geniposide on cerebral ischemic injury were assessed using MCAO mice in vivo. Geniposide treatment relieved OGD/R-triggered BV-2 cell viability promotion and apoptosis, autophagy, inflammatory response, and M1 polarization inhibition in vitro. SOX2 and RIPK1 expression was decreased in OGD/R-treated BV-2 cells. In mechanism, SOX2 upregulated RIPK1 transcription by binding to the RIPK1 promoter region. Geniposide administration significantly alleviated cerebral ischemic injury in MCAO mice in vivo. Geniposide administration protects against cerebral ischemic injury through regulating the SOX2/RIPK1 axis, providing a potential direction for the application of geniposide in the treatment of ischemic stroke.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13981-13993"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Herbal nanoparticles: bridging traditional medicine and modern science in epilepsy treatment. 草药纳米颗粒:在癫痫治疗中架起传统医学和现代科学的桥梁。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-05-07 DOI: 10.1007/s00210-025-04239-z
Homa Fazeli Kakhki, Aidin Mohammadi Zonouz, Hossein Hosseinzadeh
{"title":"Herbal nanoparticles: bridging traditional medicine and modern science in epilepsy treatment.","authors":"Homa Fazeli Kakhki, Aidin Mohammadi Zonouz, Hossein Hosseinzadeh","doi":"10.1007/s00210-025-04239-z","DOIUrl":"10.1007/s00210-025-04239-z","url":null,"abstract":"<p><p>Millions of people worldwide suffer from epilepsy, a persistent neurological illness characterized by recurring seizures. Despite advances in anti-epileptic medications, a significant number of patients continue to have insufficient seizure control and have side effects. Nanotechnology has emerged as a promising alternative for increasing medicine delivery and therapeutic effects in recent years. The anti-epileptic potential of nanoparticles produced from herbal medicines such as berberine-loaded zein/hyaluronic acid composite, Cannabis sativa extract-loaded nanoliposomes and nanostructured lipids, nanostructured lipid vehicle-carried safranal, and cryptolepine solid-lipid NPs is reviewed in this work, which makes use of the synergistic effects of nanotechnology and natural substances. The manuscript presents an overview of the mechanisms underlying the anti-epileptic effects of these nanoparticles, ranging from regulating neurotransmitter systems and ion channels to lowering oxidative stress and inflammation. Preclinical studies using animal models of epilepsy have shown that herbal medicine nanoparticles can reduce seizure activity, prolong seizure latency, and improve cognitive function. The findings presented in this manuscript highlight the remarkable potential of herbal medicine nanoparticles as a novel approach to the management of epilepsy. Continued research and development in this field have the potential to revolutionize epilepsy therapy and improve the quality of life for people suffering from this debilitating condition.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13457-13480"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behavioral deficits after traumatic brain injury: Neuroprotective effect of Diosmin. 创伤性脑损伤后的行为缺陷:地奥司明的神经保护作用。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-22 DOI: 10.1007/s00210-025-04195-8
Vida Naderi Boldaji, Mohammad Ali Mirshekar, Saiedeh Arabmoazzen, Farzaneh Faraji Shahrivar
{"title":"Behavioral deficits after traumatic brain injury: Neuroprotective effect of Diosmin.","authors":"Vida Naderi Boldaji, Mohammad Ali Mirshekar, Saiedeh Arabmoazzen, Farzaneh Faraji Shahrivar","doi":"10.1007/s00210-025-04195-8","DOIUrl":"10.1007/s00210-025-04195-8","url":null,"abstract":"<p><p>Following traumatic brain injury (TBI), the progression of brain tissue injuries and subsequent psychiatric complications considerably affect the quality of life in humans. Diosmin (DM) is a flavonoid and has been demonstrated to improve cognitive deficit and amplify brain electrical activity in the rat model of traumatic brain injury. We aimed to explore the potential protective effects of DM on single-unit neuronal firing, as well as on motor function and behaviors related to depression and anxiety associated with TBI. Forty-eight Wistar rats were randomly divided into sham-operated, TBI, and TBI + DM (100 mg/kg/day; P.O.) Groups. Depression and anxiety-like behaviors and motor function were evaluated through standard behavioral tests and Rotarod apparatus at scheduled points in time. We also measured the neuronal firing rate in the striatum. The results indicated that DM pretreatment significantly improved TBI-induced depression and anxiety-like behaviors (P < 0.01), and motor coordination (P < 0.05). The striatum neuronal firing rate in the TBI + DM Group was significantly higher than the TBI group (216 Vs 49.38 Hz, P < 0.001). The findings suggest that pretreatment with DM may offer protective benefits against TBI-associated behavioral deficits.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"14067-14074"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging the gap: a paradigm shift in medical device regulations in India. 弥合差距:印度医疗器械法规的范式转变。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-28 DOI: 10.1007/s00210-025-04197-6
Diksha Pundir, Sukhpreet Kaur, Rajinder Kaur, Ashish Baldi
{"title":"Bridging the gap: a paradigm shift in medical device regulations in India.","authors":"Diksha Pundir, Sukhpreet Kaur, Rajinder Kaur, Ashish Baldi","doi":"10.1007/s00210-025-04197-6","DOIUrl":"10.1007/s00210-025-04197-6","url":null,"abstract":"<p><p>India is among the top 20 international markets for medical devices. With increasing economic growth, rising life expectancy, and rapid technological advancements, the healthcare needs of the population have surged. This is particularly evident with the rise in chronic diseases, growing healthcare awareness, and the growing demand for personalized care and treatment. Medical devices, which encompass a wide range of machines, instruments, apparatus, and even software, play a vital role in diagnosing, treating, preventing, monitoring, and providing palliative care for various health conditions. Examples include X-ray machines, pacemakers, hip implants, ultrasound machines, glucose metres, prosthetics, and defibrillators. These devices are indispensable in the healthcare continuum across India. However, the development of India's medical device industry faces significant challenges, including limited infrastructure, outdated regulatory frameworks, and an inability to support sustainable growth. The Johnson & Johnson hip implant scandal highlighted the gaps in the existing regulatory system. The current Drugs and Cosmetics Act of 1940 (DCA, 1940) is inadequate in defining medical devices, regulating their import and manufacture, ensuring patient safety, managing adverse event reporting, and holding medical device companies accountable. To address these issues, the Medical Device Rules was introduced by the Government of India in 2017 (MDR, 2017). However, there has been a long-standing need for a more comprehensive legislative framework specifically for medical devices. To this end, the new Drugs, Medical Devices, and Cosmetics Bill of 2022 was proposed to substitute the outdated 1940 Act. This doctrinal research critically examines the shortcomings of the current DCA,1940 vis-à-vis the case study of Johnson & Johnson hip implant issue and provides a comparative analysis of this Act with the newly proposed Drugs, Medical Devices, and Cosmetics Bill of 2022.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13265-13275"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proton pump inhibitors and risk of hearing loss; a systematic review. 质子泵抑制剂与听力损失风险系统回顾。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-05-09 DOI: 10.1007/s00210-025-04241-5
Amin Khadivi, Fatemeh Amiri, Parastoo Radnia, Hanieh Salehi-Pourmehr, Fariba Mirzaei Bavil, Sina Pakkhesal, Sina Hamzehzadeh, Yalda Jabbari Moghaddam, Amirreza Naseri
{"title":"Proton pump inhibitors and risk of hearing loss; a systematic review.","authors":"Amin Khadivi, Fatemeh Amiri, Parastoo Radnia, Hanieh Salehi-Pourmehr, Fariba Mirzaei Bavil, Sina Pakkhesal, Sina Hamzehzadeh, Yalda Jabbari Moghaddam, Amirreza Naseri","doi":"10.1007/s00210-025-04241-5","DOIUrl":"10.1007/s00210-025-04241-5","url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) are widely used medications for the treatment of gastroesophageal reflux disease (GERD) and other conditions requiring acid suppression. While generally considered safe, concerns have emerged regarding potential long-term adverse effects of PPIs, such as ototoxicity. To systematically synthesize the evidence regarding the association between PPIs usage and the risk of hearing loss. This systematic review followed PRISMA guidelines. PubMed/Medline, Embase, Scopus, and Web of Science databases were searched in May 2024 and further updated using a handsearching in December 2024. Clinical original studies evaluating the relationship between PPI usage and any type of hearing impairments were included. Exclusion criteria include non-human studies, non-English language publications, reviews, case reports, book chapters, conference abstracts, and retracted studies. Risk of bias was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. The initial database search yielded 661 records. Four studies (total n = 208,956 participants) proceeded to full-text review and were included in the qualitative synthesis. All of the included studies demonstrated a statistically significant association between PPI use and an increased risk of hearing impairments; even after adjusting for possible confounders; however, one study found no independent association after adjusting for GERD symptoms. The findings of this systematic review reveal inconclusive results regarding the association between PPI use and hearing loss. While the limited available evidence suggests a possible increased risk, further research is needed to dissect the possible causal relationship and elucidate the underlying mechanisms.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13567-13580"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural product-based nanotechnological formulations for colorectal cancer treatment. 用于结直肠癌治疗的天然产品纳米技术配方。
IF 3.1 4区 医学
Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-25 DOI: 10.1007/s00210-025-04175-y
Lanfang Wu, Jiali Wu, Xinyu Wang, Youfa Xu, Zhizhe Lin, Jianming Chen, Xin Wu
{"title":"Natural product-based nanotechnological formulations for colorectal cancer treatment.","authors":"Lanfang Wu, Jiali Wu, Xinyu Wang, Youfa Xu, Zhizhe Lin, Jianming Chen, Xin Wu","doi":"10.1007/s00210-025-04175-y","DOIUrl":"10.1007/s00210-025-04175-y","url":null,"abstract":"<p><p>Colorectal cancer is one of the most common malignancies affecting the gastrointestinal tract. A silent onset often marks it and carries a poor prognosis. Studies have shown that natural products can suppress the growth of colorectal cancer and exert therapeutic effects at the molecular level. However, unfavorable physicochemical properties frequently hinder their clinical application, such as low solubility, limited bioavailability, short half-life, and rapid systemic clearance. As scientific and technological progress continues, increasing attention has been directed toward nanotechnology-based approaches. Techniques involving nanoparticles, liposomes, and micelles are being explored to improve drug delivery. These advancements provide a promising foundation for overcoming the limitations associated with natural products. This review systematically examines the application of nano-formulations for natural ingredients to offer meaningful insights into their. potential use in treating colorectal cancer.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13249-13263"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信